Movement DisordersGenetic & Genomic MedicinePeer-reviewed journal article
Diversity in Parkinson's disease genetics research: current landscape and future directions
Artur Francisco Schumacher SchuhiD, Andrei BiegeriD, Olaitan OkunoyeiD, Kin Ying MokiD, Shen‐Yang LimiD, Soraya BardieniD, Azlina Ahmad‐AnnuariD, Bruno Lopes Santos‐LobatoiD, Matheus Zschornack StrelowiD, Mohamed SalamaiD, Shilpa C. RaoiD, Yared Zenebe ZewdeiD, Saiesha DindayaliD, Jihan AzariD, Prashanth Lingappa KukkleiD, Roopa RajaniD, Alastair John NoyceiD, Njideka Ulunma OkubadejoiD, Mie RizigiD, Suzanne LesageiD, Ignacio Fernandez MataiD, Global Parkinson's Genetics Program (GP2)
Abstract
Human genetics research lacks diversity; over 80% of genome-wide association studies (GWAS) have been conducted on individuals of European ancestry. In addition to limiting insights regarding disease mechanisms, disproportionate representation can create disparities preventing equitable implementation of personalized medicine. This systematic review provides an overview of research involving Parkinsons disease (PD) genetics in under-represented populations (URP), and sets a baseline to measure the future impact of current efforts in those populations. We searched PubMed and EMBASE until October 2021 using search strings for "PD", "genetics", the main "URP", and "lower-to-upper-middle-income countries". Inclusion criteria were original studies, written in English, reporting genetic results on PD patients from non-European populations. Two levels of independent reviewers identified and extracted relevant information. We observed considerable imbalances in PD genetic studies among URP. Asian participants from China were described in the majority of the articles published (61%), but other populations were less well studied, for example, Blacks were represented in just 4.0% of the publications. Also, although idiopathic PD was more studied than monogenic forms of the disease, most studies analyzed a limited number of genetic variants. We identified just seven studies using a genome-wide approach published up to 2021 including URP. This review provides insight into the significant lack of population diversity in PD research highlighting the urgent need for better representation. The Global Parkinsons Genetics Program (GP2) and similar initiatives aim to impact research in URP, and the early metrics presented here can be used to measure progress in the field of PD genetics in the future.
- organism: human
- assay: GWAS summary statistics
- research focus: benchmarking
- approach: statistical model
- Citations
- 98
- FWCI
- 9.34
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Global Landscape of Genetic Variation in Parkinson's disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance
Lara Mariah Lange, Zih‐Hua Fang, … the Global Parkinson’s Genetic Program (GP2)·medRxiv·Jul 8, 2025
- Whole-genome sequencing of 197 cases with Parkinson's Disease reveals novel pathogenic variants in the Indian population
Hiba Ali, Banashree Mondal, … Shweta Ramdas·npj Parkinson s DiseasePeer-reviewed·Jul 6, 2026
- The genetic drivers of juvenile, young, and early-onset Parkinson's Disease in India
Shan V. Andrews, Prashanth Lingappa Kukkle, … Vedam Lakshmi Ramprasad·Movement DisordersPeer-reviewed·Nov 28, 2023
- Investigation of Autosomal Genetic Sex Differences in Parkinsons disease
Cornelis Blauwendraat, Hirotaka Iwaki, … Andrew Singleton·Annals of NeurologyPeer-reviewed·Apr 26, 2021
- Novel Parkinson's Disease Genetic Risk Factors Within and Across European Populations
The Global Parkinson’s Genetics Program (GP2), Hampton L. Leonard·medRxiv·Mar 14, 2025
- Global Perspectives on Returning Genetic Research Results in Parkinson's Disease
Ai Huey Tan, Paula Saffie Awad, … the Global Parkinson’s Genetics Program (GP2)·Neurology GeneticsPeer-reviewed·Dec 1, 2024